Marex Group’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$505K Sell
14,900
-7,629
-34% -$254K ﹤0.01% 696
2026
Q1
$679K Sell
22,529
-3,518
-14% -$113K ﹤0.01% 536
2025
Q4
$813K Sell
26,047
-5,306
-17% -$131K 0.01% 443
2025
Q3
$633K Buy
31,353
+3,698
+13% +$65K ﹤0.01% 440
2025
Q2
$463K Buy
27,655
+4,155
+18% +$67K ﹤0.01% 384
2025
Q1
$361K Buy
+23,500
New +$420K 0.01% 416
2023
Q3
– Sell
-269,686
Closed -$2.03M – 259
2023
Q2
$2.03M Buy
269,686
+153,561
+132% +$1.25M 0.37% 56
2023
Q1
$1.03M Buy
+116,125
New +$1.15M 0.14% 104

Other funds holding TEVA

Marex Group's TEVA Position: Q2 2026 in Review

Marex Group reduced its Teva Pharmaceutical Industries Limited (TEVA) stake by 34% in Q2 2026, selling an estimated $254K and leaving 14,900 shares worth $505K. The position accounts for ﹤0.01% of the portfolio, ranked #696.

Marex Group first reported a position in TEVA in Q1 2023 and has held it in 8 quarters since. The position peaked at $2.03M in Q2 2023. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Marex Group held 14,900 shares of Teva Pharmaceutical Industries Limited worth $505K as of Q2 2026.
  • Marex Group sold 7,629 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $254K.
  • Teva Pharmaceutical Industries Limited made up ﹤0.01% of Marex Group's portfolio in Q2 2026, its #696 holding.
  • Marex Group first reported a position in Teva Pharmaceutical Industries Limited in Q1 2023 and has held it in 8 quarters since.
  • Marex Group's Teva Pharmaceutical Industries Limited position peaked at $2.03M in Q2 2023.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Marex Group's 13F filing for Q2 2026, filed 14 Aug 2026.